Relationship between clopidogrel responsiveness and CYP2C19 genotype by thromboelastography in patients with coronary heart disease after PCI
| Autor: | Feihuan HU, Heng YANG, Pushan ZHANG, Ximing LI, Hanshen YE |
|---|---|
| Jazyk: | čínština |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Zhongguo shuxue zazhi, Vol 35, Iss 5, Pp 500-503 (2022) |
| Druh dokumentu: | article |
| ISSN: | 1004-549X 1004-549x |
| DOI: | 10.13303/j.cjbt.issn.1004-549x.2022.05.006&lang=en |
| Popis: | Objective To explore the relationship between clopidogrel responsiveness and CYP2C19 gene polymorphism by thromboelastography(TEG) after PCI in patients with coronary heart disease, and its guiding significance for the use of clopidogrel after PCI. Methods A total of 246 patients who underwent PCI surgery in our hospital from June 2018 to May 2021 and routinely took clopidogrel maintenance treatment after the operation were selected.The platelet inhibition rate of the patients was detected by TEG to obtain their response to clopidogrel.The CYP2C19 genotype was detected, and the relationship between the patient′s responsiveness to clopidogrel and the CYP2C19 genotype was analyzed. Results The CYP2C19 genotypes in 246 patients were fast metabolizer (n=95), intermediate metabolizer (n=104) and slow metabolizer (n=47), with the mean ADP inhibition rate(%) at 46.27±21.41, 40.99±25.53 and 24.77±21.68, respectively.They were divided into clopidogrel resistant group (n=98) and clopidogrel normal response group (n=148). The three groups of patients with different CYP2C19 genotypes had no statistically significant differences in gender composition, age and platelet count (P>0.05), while significant differences in hypertension, diabetes and hyperlipidemia(P0.05), but they were all lower than those with slow metabolism patients (both P0.5). Statistically significant difference was noticed in the low responsiveness to clopidogrel by different CYP2C19 genotypes (P |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|